Racial Preferences in Treating Kidney Disease
Guest post by Paul Williams, PhD
Photo: Wikimedia Commons
Chronic kidney disease (CKD) affects over 37 million Americans. In 2022, two preeminent kidney organizations made changes in their diagnosis of CKD. These changes were not the result of scientific discovery, but rather the National Kidney Foundation (NKF) and the American Society of Nephrologists (ASN) bowed to political pressure to ignore biological differences between races.
The changes are projected to disqualify medical treatment in 5.51 million and curtail treatment in 4.59 million White, Hispanic, and other non-Black adults with CKD. This was done in order to qualify 434,000 ostensibly unaffected Blacks for CKD treatment and to expand treatment opportunities in another 584,000 Black CKD patients.
